Search

Displaying results 5101 - 5110 of 8974 in total
  1. Drug

    DPI-221

    go.drugbank.com/drugs/DB06121
    Experimental

    DPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.

  2. Drug

    Ulinastatin

    go.drugbank.com/drugs/DB12038
    Investigational

    Ulinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.

  3. Drug

    Coblopasvir

    go.drugbank.com/drugs/DB15315
    Investigational

    Coblopasvir is under investigation in clinical trial NCT03416491 (Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C).

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Chlorophetanol

    go.drugbank.com/drugs/DB11368
    Experimental

    Chlorophetanol is an agent known to have antifungal activities.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  5. Indication

    Mucopolysaccharidosis Type I (MPS I)

    go.drugbank.com/conditions/DBCOND0065667
    Drugs: Laronidase
    Synonyms: Mucopolysaccharidosis type I severe form, Mucopolysaccharidosis type I mild form
  6. Drug

    Ketazolam

    go.drugbank.com/drugs/DB01587
    ApprovedWithdrawn

    Ketazolam is not approved in Canada or America.

  7. Drug

    GMK

    go.drugbank.com/drugs/DB06661
    Experimental

    GMK vaccine (a ganglioside conjugate vaccine coupled to keyhole limpet hemocyanin and formulated with the adjuvant QS-21) for the potential treatment of melanoma

  8. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma. … AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours.

  9. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  10. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. … COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders.